Key result
A 57-year-old female with non-small cell lung cancer developed atypical Takotsubo cardiomyopathy following four cycles of combination chemo-immunotherapy with carboplatin, pemetrexed, and pembrolizumab.
Why the study?
Anticancer therapies have emerged as causes of Takotsubo cardiomyopathy, but strong evidence linking immunotherapy to cardiomyopathy is lacking.
Does combined chemo-immunotherapy (carboplatin, pemetrexed, pembrolizumab) cause atypical Takotsubo cardiomyopathy in patients with non-small cell lung cancer?
Case Report (n=1)
Does combined chemo-immunotherapy (carboplatin, pemetrexed, pembrolizumab) cause atypical Takotsubo cardiomyopathy in patients with non-small cell lung cancer?
This case report highlights a potential association between atypical Takotsubo cardiomyopathy and the combination of carboplatin, pemetrexed, and pembrolizumab, emphasizing the need for physician awareness of this potential cardio-oncologic toxicity.
Takotsubo cardiomyopathy (TC) also known as broken heart syndrome or stress-induced cardiomyopathy is a relatively rare and transient form of cardiomyopathy. It usually mimics myocardial infarction in terms of clinical and electrocardiographic presentation, but coronary angiography usually does not reveal any evidence of coronary artery occlusion. Even though many underlying causes including emotional, physical or physiological stress have been identified, the exact pathogenesis remains uncertain. Few of anticancer therapies have been reported as an emerging cause of TC; however, no strong evidence of immunotherapy causing cardiomyopathy. We here present a very rare case of atypical TC in a 57-year-old female with advanced stage non-small cell lung cancer who underwent combined cytotoxic chemotherapy and immunotherapy with carboplatin, pemetrexed and pembrolizumab.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2020) conducted a case report in Non-small cell lung cancer (n=1). Carboplatin, pemetrexed, and pembrolizumab was evaluated on Development of atypical Takotsubo cardiomyopathy. A 57-year-old female with non-small cell lung cancer developed atypical Takotsubo cardiomyopathy following four cycles of combination chemo-immunotherapy with carboplatin, pemetrexed, and pembrolizumab.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: